精神医学の喫煙削減に関する介入研究 (TABAPSY)
外来精神医学で治療されたメンタルヘルスユーザーの喫煙を減らすための介入の評価
The smoking rate among people with mental disorders is higher than in the general population. Greater exposure to the harmful effects of tobacco partly explains the major inequality in life expectancy observed among people with mental disorders who, depending on the disorder and the study, live 10 to 25 years less than the general population, a gap mainly due to the occurrence of cardiovascular and respiratory pathologies, notably bronchial cancers. However, tobacco reduction actions specifically targeting these people remain insufficiently developed, particularly in psychiatry where this addiction is often banalized and its treatment neglected.
The objective of this study is to evaluate an intervention ('Tabapsy') co-constructed with mental health services users, mental health professionals, and general practitioners and targeting adult patients followed in ambulatory psychiatry. The main objective is to evaluate the effectiveness of the intervention on short-term smoking cessation (cessation for at least 7 days) among regular smokers at 3 months. Secondary objectives include evaluation of its cost-effectiveness and implementation. To this end, a national cluster-randomized controlled study will be carried out, supplemented by qualitative interviews to study the implementation of the intervention.
調査の概要
詳細な説明
The smoking rate among people with mental disorders is higher than in the general population. Greater exposure to the harmful effects of tobacco partly explains the major inequality in life expectancy observed among people with mental disorders who, depending on the disorder and the study, live 10 to 20 years less than the general population, a gap mainly due to the occurrence of cardiovascular and respiratory pathologies, notably bronchial cancers.
While studies found that people under psychiatric care are as motivated as others to stop smoking, the literature also shows that psychiatric care systems tolerate, underestimate and even encourage smoking among users, despite the fact that psychiatric care, whether at hospital or in an ambulatory setting, is conducive to changes in smoking behaviour and to the implementation of a smoking cessation approach, notably because of anti-smoking regulations in hospitals. In addition, withdrawal symptoms is stronger in this population and smoking cessation would therefore need to be adapted.
Against this backdrop, a smoking cessation intervention ('Tabapsy') was co-constructed with the various stakeholders (users with mental disorders, mental health professionals and general practitioners). Its aim is to encourage and support smoking cessation among people with mental disorders followed in ambulatory psychiatry by medical psychological centers (CMP). It consists of two parts: a campaign to promote smoking cessation within the CMP, and the setting up of an intervention to help people stop smoking. The latter comprises of:
- A general information meeting, to encourage motivation to start smoking cessation;
- An assessment workshop, to evaluate level of dependence using validated tests and establish a personalized cessation program based on the results obtained;
- Five thematic workshops to support cessation, covering 1/ nicotine replacement treatments, electronic cigarettes and other drug treatments available for smoking cessation, 2/ emotional management, 3/ weight gain, 4/ physical activities, and 5/ manual occupations;
- Peer support groups, based on the sharing of experiences, to encourage mutual aid and solidarity between people with mental disorders who are trying to quit smoking.
The intervention also relies on a facilitator specifically recruited to set up the intervention and run the various workshops in the CMP. It is complemented by a website that will contain all the resources and information presented during the meetings/workshops.
The primary objective of the study is to evaluate the effectiveness of the "Tabapsy" intervention on short-term smoking cessation (cessation for at least 7 days) at 3 months among regular smokers followed by adult psychiatric CMPs. Secondary objectives include assessing its cost-effectiveness and implementation.
A cluster-randomized controlled trial will be carried out to evaluate the intervention. The cluster is the "psychiatric sector", i.e., the public care entity responsible for organizing the mental health care of a population within a pre-specified geographical area (including hospital and ambulatory care) in France. A psychiatric sector may include one or multiple CMPs depending on the size of the population it serves. Psychiatric sectors will be randomized into one of two groups (intervention or usual practice).
It will be supplemented by a qualitative study to study the implementation of the intervention.
All regular smokers (at least one cigarette a day) who agree to participate will be asked to complete questionnaires on a WebApp at inclusion, and again at 3 and 6 months. Additional questionnaires will be available in the intervention group. Questions will focus on user characteristics, tobacco consumption, level of nicotine dependence, motivation to quit, use of cessation aids, level of mental and physical well-being, smoking-related knowledge and representations, and in the intervention group, participation in the intervention and satisfaction.
6,250 participants will be included over 12 months, in 22 participating sectors.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Jean-Luc ROELANDT, MD
- 電話番号:+33 3 20 43 71 00
- メール:jean-luc.roelandt@ghtpsy-npdc.fr
研究場所
-
-
-
Saint-Claude、グアドループ、97122
- 募集
- Public mental health establishment of Guadeloupe (96G06)
-
コンタクト:
- Isabelle DELAROZIERE, MD
- 電話番号:+590 5 90 41 48 68
- メール:isabelle.delaroziere@epsm-guadeloupe.fr
-
主任研究者:
- Isabelle DELAROZIERE, MD
-
Saint-Claude、グアドループ、97122
- 募集
- Public mental health establishment of Guadeloupe (96G01)
-
コンタクト:
- Daniel CAPERET, MD
- 電話番号:+590 5 90 80 52 62
- メール:Daniel.CAPERET@epsm-guadeloupe.fr
-
主任研究者:
- Magloire MPEMBI, MD
-
-
-
-
-
Armentières、フランス、59280
- 完了
- Public mental health establishment of Lille Metropole (59G16-G17)
-
Armentières、フランス、59280
- 完了
- Public mental health establishment of Lille Metropole (59G21)
-
Bailleul、フランス、59270
- 完了
- Flanders public mental health establishment (59G05/06)
-
Laxou、フランス、54520
- 完了
- Psychotherapeutic center of Nancy (54G02-06)
-
Lille、フランス、59000
- 引きこもった
- University Hospital Center of Lille (59G08)
-
Nanterre、フランス、92014
- 完了
- Hospital Care Center of Nanterre (92G10)
-
Paris、フランス、75014
- 完了
- University Hospital Group Paris Neurosciences & Psychiatry (75G04)
-
Rouffach、フランス、68250
- 完了
- Hospital Center of Rouffach (68G02/03)
-
Rouffach、フランス、68250
- 完了
- Hospital Center of Rouffach (68G08/09)
-
Rouffach、フランス、68250
- 完了
- Hospital Center of Rouffach (Pôle LTD - 68G04/05)
-
Saint-Maurice、フランス、94410
- 完了
- Hospitals of Paris Est Val de Marne (94G01)
-
Saint-Maurice、フランス、94410
- 完了
- Hospitals of Paris Est Val de Marne (94G16)
-
Saint-Maurice、フランス、94410
- 完了
- Hospitals of Paris Est Val de Marne (Paris 11)
-
Saint-Maurice、フランス、94410
- 完了
- Hospitals of Paris Est Val de Marne (Paris 12)
-
Saint-Maurice、フランス、94410
- 完了
- Hospitals of Paris Est Val de Marne (Paris Centre)
-
Saint-Venant、フランス、62350
- 完了
- Public mental health establishment of Val de Lys Artois (62G09)
-
Saint-Venant、フランス、62350
- 完了
- Public mental health establishment of Val de Lys Artois (62G12)
-
Saint-Venant、フランス、62350
- 完了
- Public mental health establishment of Val de Lys Artois (Pôle du Ternois)
-
Étampes、フランス、91150
- 募集
- Barthelemy Durand public health establishment (91G05)
-
コンタクト:
- Amina AMRANDI, MD
- 電話番号:+ 33 1 69 46 86 66
- メール:amina.amrandi@eps-etampes.fr
-
主任研究者:
- Amina AMRANDI, MD
-
-
-
-
-
Saint-Paul、再会、97460
- 完了
- Public mental health establishment of Reunion Island (Pôle Nord)
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Regular smokers (at least one cigarette per day)
- Followed in psychiatric ambulatory care at one of the participating sectors' CMPs
- Adults (18 years or older)
- Covered by the statuary health insurance
- Who gave their informed consent to participate to the study
Exclusion Criteria:
- Users under guardianship or legal protection,
- Psychological state incompatible with completing the questionnaire,
- Persons with no command or understanding of the French language
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Intervention arm
Sectors randomized to the intervention group will implement the 'Tabapsy' intervention. |
The Tabapsy intervention consists in a campaign to promote smoking cessation within the CMP, and an intervention to help people stop smoking which comprises of a) A general information meeting; b) An assessment workshop, to evaluate level of dependence using validated tests and establish a personalized cessation program based on the results obtained; c) Five thematic workshops to support cessation, covering 1/ nicotine replacement treatments, electronic cigarettes and other drug treatments available for smoking cessation, 2/ emotional management, 3/ weight gain, 4/ physical activities, and 5/ manual occupations; d) Peer support groups, based on the sharing of experiences, to encourage mutual aid and solidarity between people with mental disorders who are trying to quit smoking. The intervention relies on a facilitator specifically recruited to implement and run the intervention in the CMP. It is complemented by a website that will contain all the resources and information presented dur |
|
他の:Usual care
Sectors randomized to the control group will continue implementing their usual smoking cessation promotion. |
Usual care corresponds to usual practices regarding smoking cessation activities in participating sectors. Those practices may vary (enquiring whether a patient is a smoker or not, offering smoking cessation if they are or only if the patient asks, etc.) |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Short-term smoking cessation
時間枠:3 months
|
Short-term smoking cessation corresponds to a smoking cessation of at least 7 days, assessed among regular smoker (at least one cigarette a day) included in the study. |
3 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Motivation to stop smoking
時間枠:3 and 6 months
|
The motivation to stop smoking will be assessed using the Q-Mat ("Questionnaire de motivation à l'arrêt du tabac") scale. The computed score ranges from 0 to 20, 20 representing the highest motivation. |
3 and 6 months
|
|
Voluntary quit attempts lasting at least 24 hours in the last 3 months
時間枠:3 and 6 months
|
Number of voluntary quit attempts assessed both as percentage of users reporting at least one quit attempt and mean number of quit attempts per use |
3 and 6 months
|
|
Voluntary quit attempts lasting at least 7 days in the last 3 months
時間枠:3 and 6 months
|
Number of voluntary quit attempts assessed both as percentage of users reporting at least one quit attempt and mean number of quit attempts per user. |
3 and 6 months
|
|
Tobacco consumption
時間枠:3 and 6 months
|
Number of cigarettes smoked per day |
3 and 6 months
|
|
Nicotine dependence
時間枠:3 and 6 months
|
Nicotine dependence will be measured by the 6-question Fagerström test. |
3 and 6 months
|
|
Short-term smoking cessation
時間枠:6 months
|
Short-term smoking cessation corresponds to a smoking cessation of at least 7 days, assessed among regular smoker (at least one cigarette a day) included in the study. |
6 months
|
|
Medium-term smoking cessation
時間枠:At 3 and 6 months
|
Medium-term smoking cessation corresponds to a smoking cessation of at least 30 days, assessed among regular smoker (at least one cigarette a day) included in the study. |
At 3 and 6 months
|
|
Use of smoking cessation aids
時間枠:3 and 6 months
|
Number of participants using smoking cessation aids (nicotine replacement therapy and other smoking cessation medications (varenicline or bupropion), electronic cigarettes, and health professionals, assessed together and separately |
3 and 6 months
|
|
Level of mental well-being
時間枠:3 and 6 months
|
Level of mental well-being assessed with a visual analog scale ranging from 1 to 10, 10 representing the highest level of mental well-being |
3 and 6 months
|
|
Level of physical well-being
時間枠:3 and 6 months
|
Level of physical well-being assessed with a visual analog scale ranging from 1 to 10, 10 representing the highest level of physical well-being |
3 and 6 months
|
|
Knowledge and representations surrounding tobacco use
時間枠:3 and 6 months
|
Knowledge and representations surrounding tobacco use will be assessed using a dedicated questionnaire addressed to all the included population as well as to patients who participated to a given workshop |
3 and 6 months
|
|
Cost-effectiveness (short-term)
時間枠:A 6 months
|
Incremental cost-effectiveness ratio in cost per additional weaning of at least 7 days. |
A 6 months
|
|
Cost-effectiveness (long-term)
時間枠:6 months
|
Incremental cost-effectiveness ratio in cost per life-year gained over the entire life of users, using extrapolated data and economic modeling (Markov model) to assess lifetime costs and effectiveness 'till all patients in the model are deceased. |
6 months
|
|
Budgetary impact (costs)
時間枠:5 years after hypothetical generalization
|
Direct costs will be calculated with and without the Tabapsy intervention to assess the budgetary impact of its generalization. |
5 years after hypothetical generalization
|
|
Budgetary impact (health benefits)
時間枠:5 years after hypothetical generalization
|
The number of users who have stopped smoking for at least 7 days will be calculated with and without the Tabapsy intervention to assess the health gains associated with its generalization. |
5 years after hypothetical generalization
|
|
Implementation
時間枠:6 months
|
The implementation of the intervention and its components will be assessed using qualitative methods through semi-structured interviews conducted with 25 mental health users et 25 mental health professionnals of the intervention group). |
6 months
|
|
Satisfaction level
時間枠:3 and 6 months
|
Users who participated in one of the components of the intervention will be asked to rate their satisfaction using a visual analog scale ranging from 0 to 10, with 10 corresponding to the highest satisfaction. |
3 and 6 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Jean-Luc ROELANDT, MD、GCS-CCOMS & INSERM ECEVE 1123
- スタディディレクター:Karine CHEVREUL, MD and Pr of public health、Evaluation and research in health services and policies for vulnerable populations, French National Institute for Health and Medical Research (INSERM ECEVE 11 23)
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。